Dechra has launched Cyclofin, a fast-acting, injectable single-dose solution for acute bovine respiratory disease (BRD) caused by oxytetracycline sensitive Mannheimia (Pasteurella) haemolytica and Pasteurella multocida where an anti-inflammatory and anti-pyretic effect is required.
Cyclofin has proven efficacy in treating BRD and is a convenient, single-dose injectable combining two actives.
Flunixin-meglumine 200mg/ml (equal to 33.2mg/ml flunixin meglumine) is a potent and trusted anti-inflammatory, while oxytetracycline 300mg/ml (equal to 323.5mg/ml oxytetracycline trihydrate) is a first choice anti-infective (class D).
Cylofin acts within 24 to 36 hours and has sustained anti-bacterial activity for five to six days following a single intramuscular injection.
Administration is deep intramuscular injection in cattle and Cyclofin has a 35-day withdrawal period and a memorable dose rate of 1ml per 10kg body weight. It is both convenient to use on farm and is good value for farm vets.
Alana McGlade MRCVS, national sales manager at Dechra, comments: “Bovine respiratory disease (BRD) is one of the most prevalent and costly diseases on farm.
“Early administration of an effective and fast-acting NSAID/antibiotic combination treatment, such as Cyclofin, can help relieve discomfort and stress, alleviate pain and improve demeanour and food intake.”
Cyclofin is available in 100ml vials.
For further information on Cyclofin, visit the Dechra website or contact your local Dechra key account manager.
